[A22-101] Selinexor (multiple myeloma, fifth line) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2023
Project no.:
A22-101
Commission:
Commission awarded on 29.09.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
adult patients with multiple myeloma who have received at least four previous treatments and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy
added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-100 | Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V | Commission completed |